{"id":2944,"date":"2018-10-26T05:30:00","date_gmt":"2018-10-26T05:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-perfusion-ab-publ-interim-report-january-september-2018\/"},"modified":"2018-10-26T05:30:00","modified_gmt":"2018-10-26T05:30:00","slug":"xvivo-perfusion-ab-publ-interim-report-january-september-2018","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-interim-report-january-september-2018\/","title":{"rendered":"XVIVO Perfusion AB (publ) Interim Report January \u2013 September 2018"},"content":{"rendered":"
GOOD SALES GROWTH DRIVEN BY WARM PERFUSION<\/strong><\/div>\n

THIRD QUARTER 2018 (JUL – SEP) <\/span><\/p>\n

\u2022 Total net sales in the quarter amounted to SEK 40.9 (32.3) million, corresponding to an increase of 27 percent. The increase corresponds to 18 percent in local currency. Net sales of non-durable goods in the quarter amounted to SEK 40.3 (31.6) million, corresponding to an increase of 27 percent in SEK. Sales of non-durable goods increased by 18 percent in local currency.
<\/span>\u2022 Sales from warm perfusion* showed a growth record of more than 60 percent during the quarter. Sales from warm perfusion represented 40 percent (30) of sales of non-durable goods.
\u2022 Operating income before depreciation and amortization (EBITDA) amounted to SEK 5.2 (4.1) million, corresponding to an EBITDA margin of 13 percent. In comparison the operating income before depreciation and amortization (EBITDA) for the same quarter 2017, excluding items affecting comparability, amounted to SEK 4.4 million, corresponding to an EBITDA margin, excluding items affecting comparability, of 14 percent.
\u2022 Operating income amounted to SEK 0.7 (0.4) million, after amortization and depreciation of SEK 4.5 (3.7) million.
\u2022 Net income amounted to SEK 0.1 (-0.4) million, resulting in earnings per share of SEK 0.00 (-0.01).
\u2022 Cash flow from operating activities was SEK 3.7 (7.6) million.
\u2022 Pefadex Plus, an improved version of Perfadex, has been launched in the USA
\u2022 XVIVO\u2019s new prototype of a heart preservation machine has been pre-clinically tested with good results.<\/p>\n

THE PERIOD 2018 (JAN – SEP)<\/span><\/p>\n

\u2022 Total net sales amounted to SEK 129.5 (106.8) million, corresponding to an increase of 21 percent. The increase corresponds to 19 percent in local currency. Net sales of non-durable goods for the period amounted to SEK 120.4 (101.6) million, corresponding to an increase of 19 percent in SEK. Sales of non-durable goods increased by 16 percent in local currency.
<\/span>\u2022 Sales from warm perfusion* represented 40 percent (32) of sales of non-durable goods.
\u2022 Operating income before depreciation and amortization (EBITDA) amounted to SEK 20.4 (13.4) million, corresponding to an EBITDA margin of 16 percent. In comparison the operating income before depreciation and amortization (EBITDA) for the same period 2017, excluding items affecting comparability, amounted to SEK 15.7 million, corresponding to an EBITDA margin, excluding items affecting comparability, of 15 percent.
\u2022 Operating income amounted to SEK 7.9 (2.4) million, after amortization and depreciation of SEK 12.6 (11.1) million.
\u2022 Net income amounted to SEK 7.8 (0.7) million, resulting in earnings per share of SEK 0.30 (0.03).
\u2022 Cash flow from operating activities was SEK 26.0 (14.3) million.
\u2022 PMA application for STEEN Solution \u2122 and XPS\u2122 was filed with the FDA.
\u2022 Perfadex Plus, an upgraded version of Perfadex, has been launched in Europe and the USA.
\u2022 Analysis of the PrimECC \u00ae<\/sup>-study showed that the product is safe and showed positive clinical results.
\u2022 United Therapeutics and XVIVO Perfusion initiated a collaboration and United Therapeutics intends to use XVIVO Perfusion\u2019s products in their organ assessment services.
\u2022 SEK 19 million share issue as a result of warrants being exercised.
\u2022 Reimbursement codes (so called CPT codes) have been valid in the USA since 1 January, 2018. The new codes simplify the reimbursement process for hospitals on the American market.
\u2022 4 XPS\u2122 were delivered during the period. At the end of the period 47 hospitals had access to either XPS\u2122 or LS\u2122.<\/p>\n

CONFERENCE CALL<\/span><\/p>\n

CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on Friday, October 26, 2018. Telephone UK: +44 (0) 3333 0008 04 or USA: +1 631 913 1422, enter code 83059919#.<\/span><\/p>\n

October 26, 2018
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO<\/span>\u00a0<\/p>\n

* STEEN Solution\u2122 and products and services related to XPS\u2122 and LS\u2122.\u00a0<\/span><\/p>\n

\n

For further information please contact:<\/span><\/p>\n

Christoffer Rosenblad, CFO, +46 735 192159, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com<\/span>
For further information on XVIVO Perfusion\u2019s business, please refer to the company\u2019s website, www.xvivoperfusion.com<\/span><\/p>\n

This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation.\u00a0\u00a0The information was submitted for publication, through the agency of the contact person set out above, at 07:30 am CET on October 26, 2018.<\/span><\/p>\n

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

GOOD SALES GROWTH DRIVEN BY WARM PERFUSION THIRD QUARTER 2018 (JUL – SEP) \u2022 Total net sales in the quarter…<\/p>\n","protected":false},"template":"","class_list":["post-2944","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q3","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory"],"acf":[],"yoast_head":"\nXVIVO Perfusion AB (publ) Interim Report January \u2013 September 2018 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-interim-report-january-september-2018\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO Perfusion AB (publ) Interim Report January \u2013 September 2018 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"GOOD SALES GROWTH DRIVEN BY WARM PERFUSION THIRD QUARTER 2018 (JUL – SEP) \u2022 Total net sales in the quarter...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-interim-report-january-september-2018\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-interim-report-january-september-2018\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-interim-report-january-september-2018\\\/\",\"name\":\"XVIVO Perfusion AB (publ) Interim Report January \u2013 September 2018 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2018-10-26T05:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-interim-report-january-september-2018\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-interim-report-january-september-2018\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-interim-report-january-september-2018\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO Perfusion AB (publ) Interim Report January \u2013 September 2018\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO Perfusion AB (publ) Interim Report January \u2013 September 2018 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-interim-report-january-september-2018\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO Perfusion AB (publ) Interim Report January \u2013 September 2018 - XVIVO","og_description":"GOOD SALES GROWTH DRIVEN BY WARM PERFUSION THIRD QUARTER 2018 (JUL – SEP) \u2022 Total net sales in the quarter...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-interim-report-january-september-2018\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-interim-report-january-september-2018\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-interim-report-january-september-2018\/","name":"XVIVO Perfusion AB (publ) Interim Report January \u2013 September 2018 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2018-10-26T05:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-interim-report-january-september-2018\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-interim-report-january-september-2018\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-interim-report-january-september-2018\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO Perfusion AB (publ) Interim Report January \u2013 September 2018"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2944","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}